Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVSOLA vs GLYSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Crohn's disease (moderate to severe, fistulizing),Pediatric Crohn's disease (moderate to severe),Ulcerative colitis (moderate to severe),Pediatric ulcerative colitis (moderate to severe),Rheumatoid arthritis (in combination with methotrexate),Ankylosing spondylitis,Psoriatic arthritis,Plaque psoriasis (chronic severe)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Infliximab is a monoclonal antibody; metabolism is via catabolism into peptides and amino acids through general protein degradation pathways (reticuloendothelial system). No involvement of CYP450 enzymes.
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Predominantly bound to soluble TNF-alpha; no specific plasma protein binding (e.g., albumin) is reported; the complex is cleared, so free drug binding is low.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Volume of distribution is approximately 0.04–0.06 L/kg, indicating limited tissue distribution primarily within the vascular space.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Bioavailability is 100% after intravenous infusion; no other routes are clinically relevant.
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
No dose adjustment required for renal impairment.
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No formal studies; use caution in hepatic impairment.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; approved for ages 6 years and older.
Not recommended for pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment; monitor for infections and adverse effects.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
WARNING: SERIOUS INFECTIONS and MALIGNANCY. Increased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections) leading to hospitalization or death; increased risk of lymphoma and other malignancies, including fatal hepatosplenic T-cell lymphoma in adolescents and young adults with inflammatory bowel disease.
None
Risk of serious infections (screen for latent TB and treat before initiation, monitor for active infections),Hypersensitivity reactions (including anaphylaxis, serum sickness),Hepatotoxicity (including hepatic failure, acute liver injury),Reactivation of hepatitis B virus,Hematologic toxicity (pancytopenia, leukopenia),Neurologic events (demyelinating disorders, seizure, optic neuritis),Heart failure exacerbation,Lupus-like syndrome,Immunogenicity (development of anti-drug antibodies leading to infusion reactions and loss of response),Malignancy (especially lymphoma, leukemia, melanoma, and Merkel cell carcinoma)
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
History of severe hypersensitivity to infliximab or any murine proteins,Moderate to severe heart failure (NYHA class III/IV),Active serious infections (including sepsis, abscesses, tuberculosis, opportunistic infections),Concurrent use with abatacept or anakinra (increased risk of infection)
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
No known food interactions. AVSOLA is administered intravenously, and its absorption is not affected by oral intake. However, patients should maintain a balanced diet to support immune function.
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
AVSOLA (infliximab-axxq) is a monoclonal antibody. Ig G crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated with low risk of major malformations. Second and third trimester exposure may increase risk of fetal immunosuppression, including neonatal lymphopenia, and vaccination risks. Avascular necrosis and congenital anomalies have been reported post-marketing but causal relationship not established. Avoid live vaccines in infants exposed in utero for 6 months.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Infliximab is excreted in breast milk in small amounts; M/P ratio (milk to plasma ratio) is approximately 0.001-0.002. Oral bioavailability in infants is low due to gastrointestinal degradation. Limited data show no adverse effects in breastfed infants. However, consider maternal dosage, infant age, and risk of immunosuppression. Benefit of breastfeeding likely outweighs minimal risk.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
Pharmacokinetics of infliximab may be altered due to increased plasma volume, renal clearance, and third-spacing during pregnancy. However, no specific dose adjustment guidelines are established. Most studies recommend maintaining standard dosing throughout pregnancy to ensure therapeutic levels. Monitor clinical response and consider therapeutic drug monitoring if needed. Postpartum, no dose adjustment required, but reassess for disease flare.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
AVSOLA (infliximab-axxq) is a biosimilar to Remicade. Pre-medicate with antihistamines and acetaminophen to reduce infusion reactions. Screen for latent TB (PPD or IGRA) and HBV before initiation. Do not administer live vaccines during therapy. Monitor for signs of infection, including opportunistic infections like histoplasmosis. Discontinue if symptoms of lupus-like syndrome or severe hepatotoxicity occur. Infusion reactions may occur up to 2 hours post-infusion; have emergency equipment available.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
AVSOLA is given as an IV infusion over at least 2 hours; you will be monitored during and after infusion.,Report any signs of allergic reaction (hives, difficulty breathing, swelling) immediately.,Seek medical help if you develop fever, chills, persistent cough, or skin changes.,Do not receive live vaccines while on AVSOLA; update vaccinations before starting.,Avoid becoming pregnant during treatment; use effective contraception.,Notify your doctor of any new or worsening symptoms, including chest pain or shortness of breath.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVSOLA vs GLYSET, answered by our medical review team.
AVSOLA is a TNF-Alpha Inhibitor that works by Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.. GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVSOLA and GLYSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVSOLA is: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.. The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVSOLA and GLYSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVSOLA is classified as Category C. AVSOLA (infliximab-axxq) is a monoclonal antibody. IgG crosses the placenta, with increasing transfer during the second and third trimesters. First trimester exposure is associated. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.